WikiJournal of Medicine/Rabeprazole/XML
<?xml version="1.0" encoding="UTF-8"?>
<doi_batch version="4.4.0" xmlns="http://www.crossref.org/schema/4.4.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.crossref.org/schema/4.4.0 http://www.crossref.org/schema/deposit/crossref4.4.0.xsd">
<head>
<depositor>
<depositor_name>wkjm</depositor_name>
<email_address><span class="nowrap">Contact[[File:At sign.svg|alt=At sign|15px|@|link=]]WikiJMed.org</span></email_address>
</depositor>
<registrant>WEB-FORM</registrant>
</head>
<body>
<journal>
<journal_metadata>
<full_title>WikiJournal of Medicine/Rabeprazole</full_title>
<abbrev_title>Wiki.J.Med.</abbrev_title>
<issn media_type='electronic'>2002-4436 / 2470-6345 / 2639-5347</issn>
<doi_data>
<doi>10.15347/WJM</doi>
<resource>http://www.WikiJMed.org/</resource>
</doi_data>
</journal_metadata>
<journal_issue>
<publication_date media_type='online'>
<year>2022</year>
</publication_date>
<journal_volume>
<volume></volume>
</journal_volume>
<issue></issue>
</journal_issue>
<journal_article publication_type='full_text'>
<titles>
<title>Rabeprazole</title>
</titles>
<contributors>
<person_name sequence='first' contributor_role='author'>
<surname></surname>
</person_name><person_name sequence='additional' contributor_role='contributors'>
<surname>et al.</surname><affiliation>Wikipedia editors of Rabeprazole</affiliation><link>https://xtools.wmflabs.org/articleinfo/en.wikipedia.org/Rabeprazole//2024-12-03</link>
</person_name>
</contributors>
<publication_date media_type='online'>
<year>2022</year>
</publication_date>
<doi_data>
<doi></doi>
<resource>https://en.wikiversity.org/wiki/WikiJournal of Medicine/Rabeprazole</resource>
</doi_data>
</journal_article>
</journal>
<article>
<permissions>
<license license-type="open-access">
<license-p>[[File:Open_Access_logo_PLoS_white.svg|11px|link=Wikipedia:Open Access]] [[File:Cc.logo.circle.svg|16px|link=Wikipedia:Creative Commons]]
This is an open access article distributed under the [http://creativecommons.org/licenses/by-sa/3.0/ Creative Commons Attribution ShareAlike License], which permits unrestricted use, distribution, and reproduction, provided the original author and source are credited.</license-p>
</license>
</permissions>
<abstract>
</p>
Rabeprazole is a proton pump inhibitor that suppresses gastric acid production in the stomach. Available under different brand name products as well as in a variety of combination products, rabeprazole has several medical uses concerning the management of problems of pathological gastric acid. Rabeprazole's adverse effects tend to be mild but can be serious, including deficiencies in essential nutrients, rare incidences of liver damage, and immune-mediated reactions. As a class effect, rabeprazole can increase the risk for osteoporosis, serious infections (including ''Clostridium difficile'' infections), and kidney damage. Rabeprazole can theoretically contribute to numerous drug interactions, mediated both through its metabolic properties and its direct effect on acid in the stomach, though its potential for clinically meaningful drug interactions is low. Like other medications in the proton pump inhibitor class, rabeprazole's mechanism of action involves the irreversible inhibition of proton pumps in the stomach, which are responsible for gastric acid production. Rabeprazole has a number of chemical metabolites, though it is primarily degraded by non-enzymatic metabolism and excreted in the urine. Genetic differences in a person's drug-metabolizing enzymes may theoretically affect individual responses to rabeprazole therapy, though the clinical significance of this interaction is unlikely in comparison to other proton pump inhibitors. The purpose of this review is to provide an up-to-date monograph on rabeprazole.
</p>
</abstract>
</article>
</body>
</doi_batch>
Brand-name rabeprazole tablets.
Elbreapoly, public domain